Gilad Oren 4
4 · Aprea Therapeutics, Inc. · Filed Mar 13, 2023
Insider Transaction Report
Form 4
Gilad Oren
DirectorPresident/CEO
Transactions
- Award
Common Stock
2023-03-09+4,000→ 322,770 total - Conversion
Series A Non-Voting Convertible Preferred Stock
2022-08-23−604,510→ 0 total→ Common Stock (6,045,100 underlying) - Award
Stock Options (Right to Buy)
2023-03-09+16,000→ 16,000 totalExercise: $5.08Exp: 2033-03-09→ Common Stock (16,000 underlying) - Conversion
Common Stock
2022-08-23+6,045,100→ 6,375,414 total
Footnotes (4)
- [F1]These shares represent restricted stock units ("RSUs") and shall vest and be settled in the Issuer's common stock ("Common Stock") in three (3) equal annual installments beginning on March 9, 2024 until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
- [F2]Each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of Common Stock any time at the option of the holder thereof, subject to certain limitations. On August 23, 2022, the Reporting Person converted 604,510 shares of Series A Non-Voting Convertible Preferred Stock into 6,045,100 shares of Common Stock.
- [F3]Twenty-five percent of these options vest on March 9, 2024, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
- [F4]Reflects a one-for-20 reverse split, effective as of 5:00 p.m. Eastern Time on February 10, 2023.